Study of atazanavir-induced hyperbilirubinemia among HIV patients on second-line anti-retroviral therapy

• Päätekijät: K Ravi (Tekijä), G N Devamsh (Tekijä), K J Umesh (Tekijä), B C Prashant (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Wolters Kluwer Medknow Publications, 2020-01-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Introduction: Ritonavir-boosted atazanavir (ATV/r) is the preferred second-line protease inhibitor option for HIV patients as per the NACO guidelines. Atazanavir is a protease inhibitor with several advantages including once-daily dosing, low pill burden, and favorable effect on lipid profile compar...